Novavax to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
09/07/2021 - 09:05 AM
GAITHERSBURG, Md. , Sept. 7, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in Citi's 16th Annual BioPharma Virtual Conference 2021 investor conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
Conference Details:
Fireside Chat
Date:
Thursday, September 9, 2021
Time:
4:10 – 4:55 p.m. Eastern Time (ET)
Moderator:
Michael Guba
Novavax participants:
Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer
Conference
Event:
Investor meetings
Date:
Thursday, September 9, 2021
A replay of the recorded fireside session will be available through the events page of the Company's website at ir.novavax.com for 90 days.
About Novavax Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn .
Contacts: Investors Novavax, Inc. Erika Schultz | 240-268-2022ir@novavax.com
Solebury Troutaroy@soleburytrout.com
Media Alison Chartan | 240-720-7804Laura Keenan | 202-709-7521media@novavax.com
https://www.prnewswire.com/news-releases/novavax-to-participate-in-citis-16th-annual-biopharma-virtual-conference-2021-301370261.html
SOURCE Novavax, Inc.
NVAX Rankings
#5166 Ranked by Stock Gains
NVAX Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Gaithersburg
About NVAX
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
